Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S H Hohnloser

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
European Heart Journal|July 20, 2000
Electrocardiographic risk stratification in dilative cardiomyopathy: an unfulfilled promiseS H Hohnloser
Pacing and Clinical Electrophysiology : PACE|May 1, 1994
Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillationS H Hohnloser
Der Internist|February 1, 1995
[Sotalol]S H Hohnloser
European Heart Journal|August 26, 1998
Can we predict atrial fibrillation after coronary surgery and why should we?S H Hohnloser
Journal of the American College of Cardiology|September 15, 2000
Prevention of recurrent life-threatening arrhythmias: will lipid-lowering therapy make a difference?S H Hohnloser
Journal of Cardiovascular Electrophysiology|July 27, 2001
Repolarization alternans facilitated by structural abnormalities of the heart: another piece of the puzzleS H Hohnloser
Der Internist|January 1, 1996
[Drug therapy of supraventricular and ventricular tachyarrhythmias]S H Hohnloser
The American Journal of Cardiology|November 14, 1997
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and managementS H Hohnloser
Journal of Cardiovascular Electrophysiology|June 4, 1999
Macroscopic T wave alternans as a harbinger of sudden deathS H Hohnloser
The American Journal of Cardiology|November 24, 1999
Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillationS H Hohnloser
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
European Heart Journal|July 20, 2000
Electrocardiographic risk stratification in dilative cardiomyopathy: an unfulfilled promiseS H Hohnloser
Pacing and Clinical Electrophysiology : PACE|May 1, 1994
Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillationS H Hohnloser
Der Internist|February 1, 1995
[Sotalol]S H Hohnloser
European Heart Journal|August 26, 1998
Can we predict atrial fibrillation after coronary surgery and why should we?S H Hohnloser
Journal of the American College of Cardiology|September 15, 2000
Prevention of recurrent life-threatening arrhythmias: will lipid-lowering therapy make a difference?S H Hohnloser
Journal of Cardiovascular Electrophysiology|July 27, 2001
Repolarization alternans facilitated by structural abnormalities of the heart: another piece of the puzzleS H Hohnloser
Der Internist|January 1, 1996
[Drug therapy of supraventricular and ventricular tachyarrhythmias]S H Hohnloser
The American Journal of Cardiology|November 14, 1997
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and managementS H Hohnloser
Journal of Cardiovascular Electrophysiology|June 4, 1999
Macroscopic T wave alternans as a harbinger of sudden deathS H Hohnloser
The American Journal of Cardiology|November 24, 1999
Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillationS H Hohnloser
Pageof 16